Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

News

71 - 80of about 630 News

71 - 80of about 630 News

July 16, 2020

Not intended for U.S. and UK Media

U.S. FDA grants priority review to New Drug Application for vericiguat to treat chronic heart failure

July 09, 2020

Not intended for U.S. and UK Media

Bayer’s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes

July 08, 2020

Bayer remains committed to Roundup™ settlement

July 01, 2020

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Bayer issues new senior bonds with a volume of 6 billion euros

June 24, 2020

Bayer announces agreements to resolve major legacy Monsanto litigation

June 19, 2020

Women empowerment in times of COVID-19

Bayer supports “The Challenge Initiative” of Johns Hopkins Bloomberg School of Public Health with 10 million USD

June 17, 2020

Bayer to Provide Crop Relief to Two Million Smallholder Farmers Impacted by COVID-19

June 15, 2020

Not intended for U.S. and UK Media

Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fraction

June 05, 2020

Not intended for U.S. and UK Media

Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failure

May 29, 2020

Not intended for U.S. and UK Media - American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program):

Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancer

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases